Maddalena Noviello

Maddalena Noviello

Auto-generated profile, based on publicly available information

Maddalena Noviello

Innovative Immunotherapies Unit, IRCCS San Raffaele Hospital, Milano, Italy.

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CTCristina Toffalori
Cristina Toffalori
LZLaura Zito
Laura Zito
VGValentina Gambacorta
Valentina Gambacorta
MRMichela Riba
Michela Riba
GOGiacomo Oliveira
Giacomo Oliveira
LVLuca Vago
Luca Vago

25 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMaddalena Noviello
Maddalena Noviello
FMFrancesco Manfredi
Francesco Manfredi
EREliana Ruggiero
Eliana Ruggiero
TPTommaso Perini
Tommaso Perini
GOGiacomo Oliveira
Giacomo Oliveira
CBChiara Bonini
Chiara Bonini
The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating the bone marrow (BM) of 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) after HSCT. A higher proportion of early-differentiated Memory Stem (TSCM) and Central Memory BM-T cells express multiple IR in relapsing patients than in CR patients. Exhausted BM-T cells at relapse display a restricted TCR repertoire, impaired effector functions and leukemia-reactive specificities. In 57 patients, early detection of severely exhausted (PD-1+Eomes+T-bet−) BM-TSCM predicts relapse. Accordingly, leukemia-specific T cells in patients prone to relapse display exhaustion markers, absent in patients maintaining long-term CR. These results highlight a wide, though reversible, immunological dysfunction in the BM of AML patients relapsing after HSCT and suggest new therapeutic opportunities for the disease.

5 November 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
GCGiulio Cossu
Giulio Cossu
SPStefano Previtali
Stefano Previtali
SNSara Napolitano
Sara Napolitano
MCMaria Pia Cicalese
Maria Pia Cicalese
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco
FCFabio Ciceri
Fabio Ciceri
Intra‐arterial transplantation of mesoangioblasts proved safe and partially efficacious in preclinical models of muscular dystrophy. We now report the first‐in‐human, exploratory, non‐randomized open‐label phase I–IIa clinical trial of intra‐arterial HLA‐matched donor cell transplantation in 5 Duchenne patients. We administered escalating doses of donor‐derived mesoangioblasts in limb arteries under immunosuppressive therapy (tacrolimus). Four consecutive infusions were performed at 2‐month intervals, preceded and followed by clinical, laboratory, and muscular MRI analyses. Two months after the last infusion, a muscle biopsy was performed. Safety was the primary endpoint. The study was relatively safe: One patient developed a thalamic stroke with no clinical consequences and whose correlation with mesoangioblast infusion remained unclear. MRI documented the progression of the disease in 4/5 patients. Functional measures were transiently stabilized in 2/3 ambulant patients, but no functional improvements were observed. Low level of donor DNA was detected in muscle biopsies of 4/5 patients and donor‐derived dystrophin in 1. Intra‐arterial transplantation of donor mesoangioblasts in human proved to be feasible and relatively safe. Future implementation of the protocol, together with a younger age of patients, will be needed to approach efficacy. Synopsis This study reports a safe, first‐in‐human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non‐randomized open‐label phase I–IIa clinical trial of intra‐arterial HLA‐matched donor cell transplantation. Five patients affected by DMD were treated by intra‐arterial infusions of escalating doses of HLA‐matched donor mesoangioblasts. The trial was overall safe but showed minimal, if any, efficacy. Data analysis suggested to treat patients at an earlier stage of the disease, optimize in in vitro models each single step of the transplantation protocol, and use genetically corrected, autologous mesoangioblasts in a future trial.

30 April 2015 in Blood
Verified
Journal Article
Open access
PDF file
NCNicoletta Cieri
Nicoletta Cieri
GOGiacomo Oliveira
Giacomo Oliveira
RGRaffaella Greco
Raffaella Greco
MFMattia Forcato
Mattia Forcato
CTCristian Taccioli
Cristian Taccioli
CBChiara Bonini
Chiara Bonini
Memory stem T cells (TSCM) have been proposed as key determinants of immunological memory. However, their exact contribution to a mounting immune response as well as the mechanisms and timing of their in vivo generation are poorly understood. We longitudinally tracked TSCM dynamics in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), thereby providing novel hints on the contribution of this subset to post transplant immune reconstitution in humans. We found that donor-derived TSCM cells are highly enriched early after HSCT. We showed at the antigen-specific and clonal level that TSCM lymphocytes can differentiate directly from naïve precursors infused within the graft and that the extent of TSCM generation might correlate with IL-7 serum levels. In vivo fate mapping through TCR sequencing allowed defining the in vivo differentiation landscapes of human naïve T cells, supporting the notion that progenies of single naïve cells embrace disparate fates in vivo, and highlighting TSCM as relevant novel players in the diversification of immunological memory following allogeneic HSCT.

4 June 2014 in Leukemia
Verified
Journal Article
Closed access
PDF file
JPJ Peccatori
J Peccatori
AFA Forcina
A Forcina
DCD Clerici
D Clerici
RCRoberto Crocchiolo
Roberto Crocchiolo
LVL Vago
L Vago
FCFabio Ciceri
Fabio Ciceri

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SMSara Martina Maffioletti
Sara Martina Maffioletti
MNMaddalena Noviello
Maddalena Noviello
KEKaren English
Karen English
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco
Treating muscle disorders poses several challenges to the rapidly evolving field of regenerative medicine. Considerable progress has been made in isolating, characterizing, and expanding myogenic stem cells and, although we are now envisaging strategies to generate very large numbers of transplantable cells (e.g., by differentiating induced pluripotent stem cells), limitations directly linked to the interaction between transplanted cells and the host will continue to hamper a successful outcome. Among these limitations, host inflammatory and immune responses challenge the critical phases after cell delivery, including engraftment, migration, and differentiation. Therefore, it is key to study the mechanisms and dynamics that impair the efficacy of cell transplants in order to develop strategies that can ultimately improve the outcome of allogeneic and autologous stem cell therapies, in particular for severe disease such as muscular dystrophies. In this review we provide an overview of the main players and issues involved in this process and discuss potential approaches that might be beneficial for future regenerative therapies of skeletal muscle.